3904-24-3

Basic information

• Product Name: (5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine hydrochloride
• Synonyms: 3-(5-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propan-1-amine hydrochloride;5-Methoxy-N-propyl-1,2,3,4-tetrahydro-2-naphthalenamine hydrochloride
• CAS NO: 3904-24-3
• Molecular Formula: C₁₄H₂₁NO*ClH
• Molecular Weight: 255.78358
• Mol File: 3904-24-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 243-248 °C
• Appearance: /
• Density: 1.22g/cm3 at 20℃
• Vapor Pressure: 0-0Pa at 20-25℃
• CAS DataBase Reference: (5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine hydrochloride(3904-24-3)
• EPA Substance Registry System: (5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine hydrochloride(3904-24-3)

Safety Data

• Hazardous Substances Data: 3904-24-3(Hazardous Substances Data)

Usage

General Description

(5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine hydrochloride is a chemical compound that is a derivative of naphthalene and propylamine. It is commonly used in scientific research and drug development as a potential treatment for conditions such as depression and anxiety disorders. (5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine hydrochloride acts as a selective serotonin reuptake inhibitor, which means it is able to increase levels of serotonin in the brain by blocking its reabsorption. This can lead to improved mood and reduced symptoms of depression and anxiety. However, like other psychoactive drugs, it may also have potential side effects and interactions with other medications, so it should be used under the guidance of a qualified healthcare professional.

Upstream product

• 78598-91-1 2-(N-propylamino)-5-methoxytetraline 
• 107-10-8 propylamine 
• 32940-15-1 5-methoxy-2-tetralone 
• 101403-25-2 (R)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-amine 
• 123-38-6 propionaldehyde 
• 3880-88-4 SKF 87967 hydrochloride 

Downstream Products

• 1352917-66-8 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (R)-2-(2-chlorophenyl)-2-hydroxyacetate 
• 99755-59-6 rotigotine 
• 165950-84-5 (S)-1,2,3,4-tetrahydro-5-hydroxy-N-propyl-naphthalen-2-ammonium hydrobromide 
• 125572-93-2 rotigotine hydrochloride 
• 78598-91-1 2-(N-propylamino)-5-methoxytetraline 
• 1352917-65-7 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (R)-2-methoxy-2-phenylacetate 
• 1352917-67-9 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (S)-2-hydroxy-3-phenylpropionate 
• 93601-86-6 (S)-(-)-(5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamine hydrochloride 
• 1352917-68-0 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (S)-2-methoxy-2-phenylacetate 
• 101470-23-9 Desthienyl-Rotigotine 
• 136247-11-5 N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-2-(4-nitrophenyl)-N-propylacetamide 
• 101403-24-1 (S)-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propylamine hydrochloride 
• 101403-25-2 (R)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-amine 

Relevant articles and documents

Intensification of Free-Radical Racemization for a Non-activated Amine in a Continuous Flow Reactor

The free-radical racemization of non-activated amines is a powerful tool for process design in the pharmaceutical industry, allowing the recycling of undesired enantiomers after chiral separation. This paper describes the development of the free-radical racemization of a key API intermediate in a continuous flow reactor. Upon development, a significant reduction of the solvent usage and radical initiator was made possible thanks to the conversion into a continuous flow mode. This intensification positively impacted both the environmental footprint and the safety of the reaction as well as maintaining satisfactory productivity.

Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives

The present invention provides an alternative synthesis of N-substituted aminotetralines comprising resolution of N-substituted aminotetralins of formula (II), wherein R1, R2 and R3 are as defined for compound of formula (I).

Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl) amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: In vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease

The role of iron in the pathogenesis of Parkinson's disease (PD) has been implicated strongly because of generation of oxidative stress leading to dopamine cell death. In our overall goal to develop bifunctional/multifunctional drugs, we designed dopamine D2/D3 agonist molecules with a capacity to bind to iron. Binding assays were carried out with HEK-293 cells expressing either D2 or D3 receptor with tritiated spiperone to evaluate inhibition constants (K i). Functional activity of selected compounds was carried out with GTPyS binding assay. SAR results identified compounds (+)-19a and (-)-19b as two potent agonists for both D2 and D3 receptors (EC50 (GTPyS); D2 = 4.51 and 1.69 nM and D3 = 1.58 and 0.74 nM for (-)-19b and (+)-19a, respectively). In vitro complexation studies with 19b demonstrated efficient chelation with iron. Furthermore, the deoxyribose assay with 19b demonstrated potent antioxidant activity. In PD animal model study, (-)-19b exhibited potent in vivo activity in reversing locomotor activity in reserpinized rats and also in producing potent rotational activity in 6-OHDA lesioned rats. This reports initial development of unique lead molecules that might find potential use in symptomatic and neuroprotective treatment of PD.